Archive for January, 2013

« Previous Entries

Breastfeeding Concerns Related To Tacrolimus Not True

Thursday, January 31st, 2013

A study has revealed Tacrolimus; an immunosuppressant can be safely taken by nursing mothers as the drug does not pass to the baby through breastfeeding. Researchers added that more studies are required to confirm the safety of the drug for breastfeeding women and women taking Tacrolimus should not be discouraged from breastfeeding. The study was [...]

Group Education Beneficial For Older Diabetes Patients

Wednesday, January 30th, 2013

A randomized trial has revealed benefits of group behavioral interference are not confined to young diabetes patients only. The study revealed older diabetes patients also received good glycemic benefits of self management intervention. The report also revealed majority of the physicians do not refer older diabetes patients to group education as they have an opinion [...]

Research Upholds Safety Of Immunization Schedule For Children

Tuesday, January 29th, 2013

The Childhood Immunization Schedule and Safety report upheld the current immunization schedule safe for children and dispelled all rumors associated with safety of the immunization schedule. The immunization schedule was being questioned by stakeholders which included parents, healthcare providers, public health officials and some section of scientific community. The immunization schedule was considered unsafe, as [...]

FDA Advocates Lower Bed Time Dose Of Drugs Containing Zolpidem

Monday, January 28th, 2013

The FDA (US Food and Drug Administration) has issued a new recommendation to lower bedtime doses of medicines containing the sedative- Zolpidem. The new recommendation is applicable to all Zolpidem products that are indicated for bedtime use to treat insomnia. All brands names such as Ambien, Edluar, Ambien CR, and Zolpimist and several other generic [...]

FDA Approves Botox To Reduce Urinary Continence In Treatment Of Overactive Bladder

Monday, January 28th, 2013

Botox (onabotulinumtoxinA) has been recently approved by FDA (US Food and Drug Administration) for the treatment of overactive bladder to reduce urinary incontinence. However, the use of drug is only limited to patients who do not respond or cannot use anticholinergics to treat the condition. A Botox injection causes the bladder muscles to relax which [...]

Uceris Approved By FDA In The Treatment Of Ulcerative Colitis

Sunday, January 27th, 2013

Santarus Inc recently announced FDA given approval to Uceris, which is a Budesonide extended release drug in tablet form. This drug is used to treat adult patients who are suffering from ulcerative colitis (active mild to moderate). The treatment involves using oral form of corticosteroid Budesonide that is delivered in the body using MMX multimatrix [...]

ADHD Incidence On Rise In American Children

Saturday, January 26th, 2013

The new research conducted by Kaiser Permanente Southern California’s Department of Research has revealed rise of ADHD (attention-deficit/hyperactivity disorder) diagnosis in children of United States. The 10 year research data shows steep increase of 24%   in rate of ADHD diagnosis which is quite alarming. The research also showed disproportionate high ADHD rates in black girls [...]

Severity of Emphysema Strongest Predictor Of Respiratory Mortality

Friday, January 25th, 2013

A study published in American Journal of Respiratory and Critical Care Medicine states severity of emphysema measured by computed tomography (CT) can be used to predict mortality in current and former smokers. The prediction by CT is highly accurate irrespective of smoker having chronic obstructive pulmonary disease (COPD).  Researchers also added that airway wall thickness [...]

Open Access Scheduling In Pediatric Subspecialty Practice Decrease Waiting Time Significantly

Thursday, January 24th, 2013

New research findings have revealed that implementation of open-access scheduling has greatly reduced average waiting to 1.7 weeks which was earlier 11.4 weeks. The research findings are based on open-access scheduling adopted at an urban academic hospital faculty-based practice. Rubina A. Heptulla, MD, professor of pediatrics and medicine and division chief of Pediatric Endocrinology and [...]

European Medicine Agency Approves Bosutinib In The Treatment Of Chronic Myelogenous Leukemia

Tuesday, January 22nd, 2013

The European Medicine Agency also known as Committee for Medicinal Products for Human Use (CHMP) recently approved Bosutinib (Bosulif, Pfizer) for the treatment of chronic myelogenous leukemia (CML) in Europe.
Bosutinib, which is in fact the fourth tyrosine kinase inhibitor approved for the treatment of CML was earlier approved in the United States in September 2012. [...]

« Previous Entries